All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ReFocus Validates RLY-4008 As Active Agent for FGFR2+ Cholangiocarcinoma

September 11th 2022

High response rates and encouraging durability support RLY-4008 as a transformative treatment option for patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Nivolumab/Ipilimumab Boosting Following Nivolumab Monotherapy Increases Responses in Advanced RCC

September 11th 2022

A tailored approach utilizing the combination of nivolumab and ipilimumab as an immunotherapeutic boost following induction with single-agent nivolumab improved responses in the first and second line for patients with advanced renal cell carcinoma.

Updated ADAURA Data Reinforce Adjuvant Osimertinib as SOC for EGFR-Mutated, Stage IB-IIIA NSCLC

September 11th 2022

Adjuvant osimertinib resulted in a 77% reduction in the risk of disease recurrence or death in patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer, with a disease-free survival improvement observed irrespective of prior adjuvant chemotherapy or disease stage.

Destiny-Breast04 Update Showcases QOL Benefit With Trastuzumab Deruxtecan for HR+, HER2-Low Breast Cancer

September 11th 2022

Trastuzumab deruxtecan demonstrated a promising quality-of-life benefit for patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to a report on patient-reported outcomes from the pivotal DESTINY-Breast04 trial.

Lenvatinib/Pembrolizumab Combo Provides Continued OS, PFS Benefit in Advanced RCC

September 11th 2022

Lenvatinib plus pembrolizumab showed sustained overall survival and progression-free survival benefit across poor- and intermediate-risk subgroups of patients with advanced renal cell carcinoma.

High-Dose MEDI5752 Induces Clinical Benefit in NSCLC at the Cost of Significant Toxicity

September 11th 2022

MEDI5752 plus chemotherapy doubled the duration of response and extended survival compared with pembrolizumab in patients with treatment-naïve nonsquamous non–small cell lung cancer.

Olaparib/Abiraterone Continues to Provide Superior Clinical Benefit Over Abiraterone Alone in Frontline mCRPC

September 11th 2022

The combination of olaparib plus abiraterone acetate and prednisone or prednisolone demonstrated a continuing trend toward an overall survival benefit when used in the first-line treatment of patients with metastatic castration-resistant prostate cancer.

DCC-3116 Displays Early Tolerability in RAS/RAF-Mutant Solid Tumors

September 11th 2022

The ULK1/2 inhibitor DCC-3116 was well tolerated as a monotherapy in patients with locally advanced or metastatic tumors harboring a RAS or RAF mutation.

POU2F2 May Be Predictive of Survival Benefit With Maintenance Avelumab in Urothelial Carcinoma

September 11th 2022

The absence of POU2F2, may be predictive of response to maintenance avelumab in patients with advanced or metastatic urothelial carcinoma, according to findings from an analysis peripheral blood samples taken in the JAVELIN Bladder 100 trial.

Rucaparib Maintenance Elicits PFS Benefit in Newly Diagnosed Ovarian Cancer

September 11th 2022

First-line rucaparib maintenance therapy improved progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study.

Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer

September 11th 2022

Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.

Addition of Enzalutamide to Abiraterone/Prednisolone Deemed Unnecessary in Metastatic HSPC

September 11th 2022

Although the combination of androgen deprivation therapy, abiraterone acetate, and prednisolone showed a clinically meaningful 7-year improvement in overall survival, AAP plus enzalutamide is not recommended in patients with metastatic hormone-sensitive prostate cancer.

Adjuvant Nivolumab Plus Ipilimumab Fails to Improve DFS in Localized, High-Risk RCC

September 11th 2022

The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.

Pembrolizumab Plus Chemoradiation Shows Only Numerically Improved EFS, OS in Locally Advanced Head and Neck Cancer

September 11th 2022

Pembrolizumab plus chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck squamous cell carcinoma.

Blood-based Assay Demonstrates Positive Prognostic Value for Solid and Liquid Tumor Detection

September 11th 2022

A pan-tumor blood-based assay demonstrated a specificity of 99.1% and positive predictive value of 38.0% and resulted in a diagnosis of cancer in 35 individuals.

Tremelimumab Plus Durvalumab/Chemo Maintains OS Benefit in Metastatic NSCLC

September 11th 2022

The frontline combination of tremelimumab plus durvalumab and chemotherapy generated a long-term overall survival benefit in patients with metastatic non–small cell lung cancer.

Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCC

September 11th 2022

The addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.

Frontline Tislelizumab Demonstrates Noninferior OS Vs Sorafenib in Unresectable HCC

September 11th 2022

Tislelizumab monotherapy provided a clinically meaningful overall survival benefit that was noninferior to sorafenib and showcased a favorable toxicity profile when used as a frontline treatment for patients with unresectable hepatocellular carcinoma.

Atezolizumab Fails to Improve DFS in RCC Following Resection

September 10th 2022

Treatment with atezolizumab did not improve clinical outcomes vs placebo following resection in patients with renal cell carcinoma at increased risk of recurrence.

Perioperative Nivolumab Fails to Improve RFS Vs Surgery Alone in RCC

September 10th 2022

Perioperative nivolumab did not improve recurrence-free survival compared with surgery alone in patients with renal cell carcinoma.